W

    Whitehawk Therapeutics, Inc. (WHWK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.54
    -0.08 (-1.73%)

    Market Cap: $263.38M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(17/25)
    Avg Surprise
    -14.16%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.25
    Range$-0.27 - $-0.21
    3 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.30-21.6%
    30d ago$-0.29-16.2%
    7d ago$-0.27-8.4%
    Current$-0.25
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.20 - $-0.07
    2 analysts
    Revenue Consensus
    $262500
    Range$262500 - $262500
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$-0.25---
    Jun 26
    		$-0.20$-0.30+33.33%Beat+73.7%
    Mar 26
    		$-0.32$-0.33+3.03%Beat+11.1%
    Dec 25
    		$-0.34N/A+50.74%Beat+49.3%
    Sep 25
    		$-0.25$-0.22-13.64%Miss+32.4%
    Jun 25
    		$-0.76$0.49-255.10%Miss-40.7%
    Mar 25
    		$-0.36$-0.23-56.52%Miss+47.1%
    Dec 24
    		$-0.67$-0.21-219.05%Miss-11.7%
    Sep 24
    		$-0.37$-0.47+21.28%Beat+38.3%
    Jun 24
    		$-0.54$-0.64+15.63%Beat+19.4%
    Mar 24
    		$-0.68$-0.62-9.68%Miss-19.3%
    Dec 23
    		$-0.60$-0.65+7.69%Beat-25.0%
    Sep 23
    		$-0.60$-0.73+17.81%Beat+11.8%
    Jun 23
    		$-0.67$-0.60-11.67%Miss+2.9%
    Mar 23
    		$-0.57$-0.57+0.00%Beat+13.6%
    Dec 22
    		$-0.48$-0.72+33.33%Beat+37.7%
    Sep 22
    		$-0.68$-0.75+9.33%Beat+52.1%
    Jun 22
    		$-0.69$-0.73+5.48%Beat+48.9%
    Mar 22
    		$-0.66$-0.68+2.94%Beat-633.3%
    Dec 21
    		$-0.77$-0.77+0.00%Beat-670.0%
    Sep 21
    		$-1.42$-0.73-94.52%Miss-1083.3%
    Jun 21
    		$-1.35N/A+77.50%Beat-687.0%
    Mar 21
    		$-0.09$-0.09+0.00%Beat+93.8%
    Dec 20
    		$-0.10$-0.14+28.57%Beat+93.9%
    Sep 20
    		$-0.12$-0.14+14.29%Beat+93.0%
    Jun 20
    		$0.23$0.27-14.81%Miss+110.9%
    Mar 20
    		$-1.45N/AN/ABeat+53.9%
    Dec 19
    		$-1.64N/AN/ABeat+47.8%
    Sep 19
    		$-1.72N/AN/ABeat-140.7%
    Jun 19
    		$-2.10N/AN/ABeat+36.1%
    Mar 19
    		$-3.14N/AN/ABeat+23.8%
    Dec 18
    		$-3.15N/AN/ABeat+9.2%
    Sep 18
    		$4.22N/AN/ABeat+263.1%
    Jun 18
    		$-3.29N/AN/ABeat-
    Mar 18
    		$-4.12N/AN/ABeat-
    Dec 17
    		$-3.47N/AN/ABeat-
    Sep 17
    		$-2.59N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-4.09EV/EBITDA17.03x
    Price/FCF-5.43xFCF Yield-18.43%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-45.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio17.38xQuick Ratio17.38x
    Trading Statistics
    Beta0.78Avg Volume357.82K
    52-Week High$5.5052-Week Low$1.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.80
    SMA 20$4.67
    SMA 50$4.27
    SMA 200$3.56
    EMA 10$4.72
    EMA 20$4.61
    EMA 50$4.38
    EMA 200$3.68

    MACD

    Line: 0.16Signal: 0.19Hist: -0.03

    ADX

    ADX: 13.2+DI: 18.4-DI: 24.5

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down4.0
    PSAR$5.10

    Bollinger Bands

    Upper Band$5.15
    Lower Band$4.19
    %B Position2050%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    50.1

    Momentum Oscillators

    Stoch %K46.1
    Stoch %D63.5
    Williams %R-81.2
    ROC (10d)-2.2%
    Momentum-0.10
    CCI (20d)-54.2
    MFI (14d)52.3

    Volatility Measures

    ATR (14d)$0.28(6.1%)
    StdDev (20d)0.24
    Hist Vol74.1%(High)

    Volume Flow

    VWAP$4.52
    OBV105.0M
    AD Line-72.1M
    CMF (20d)0.010

    Volume Metrics

    Avg Vol (20d)359.3K
    Vol Ratio1.0x
    VWMA (20d)$4.61

    Pivot Points

    R3$5.33
    R2$5.18
    R1$4.90
    Pivot Point$4.75
    S1$4.47
    S2$4.32
    S3$4.04

    Advanced Oscillators

    TSI17.79
    Ultimate Osc45.4
    KST191.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$7.14M$7.24M$7.21M$6.18M$5.35M$6.33M$5.96M
    Cost of Revenue$0$0$1,000$0$0$760,000$790,000$804,000$778,000$652,000$927,000$697,000
    Gross Profit$0$0$-1,000$0$0$6.38M$6.45M$6.41M$5.40M$4.70M$5.40M$5.26M
    Operating Expenses$18.11M$23.52M$24.89M$19.55M$54.75M$21.60M$25.40M$19.82M$20.98M$24.21M$23.11M$23.11M
    R&D$12.89M$17.23M$19.02M$14.35M$48.81M$8.79M$14.35M$10.00M$13.09M$13.59M$12.77M$11.89M
    SG&A$5.22M$6.29M$5.87M$5.20M$5.94M$12.81M$11.05M$7.19M$7.89M$10.62M$10.35M$11.22M
    Operating Income$-18,109,000$-23,522,000$-24,887,000$-19,546,000$-54,749,000$-15,218,000$-18,949,000$-13,413,000$-15,584,000$-19,512,000$-17,714,000$-17,849,000
    Interest Income$1.48M$1.33M$1.61M$1.85M$1.98M$791,000$676,000$906,000$1.06M$1.28M$1.50M$1.60M
    Interest Expense$0$0$0$0$0$0$0$38,000$58,000$58,000$57,000$58,000
    Income Before Tax$-16,640,000$-22,194,000$-23,251,000$-17,746,000$-52,615,000$73.02M$-18,273,000$-12,546,000$-14,583,000$-18,289,000$-16,269,000$-16,302,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-16,640,000$-22,194,000$-23,251,000$-17,746,000$-52,615,000$73.02M$-18,273,000$-12,546,000$-14,583,000$-18,289,000$-16,269,000$-16,302,000
    EBITDA$-18,473,000$-23,868,000$-25,692,000$-20,308,000$-54,576,000$72.30M$-19,085,000$-13,676,000$-15,924,000$-19,885,000$-18,154,000$-18,393,000
    EBIT$-18,115,000$-23,522,000$-24,862,000$-19,596,000$-54,594,000$72.22M$-18,949,000$-13,414,000$-15,586,000$-19,513,000$-17,712,000$-17,849,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about WHWK

    News

    1,341,394 Shares in Whitehawk Therapeutics, Inc. $WHWK Bought by ADAR1 Capital Management LLC

    ADAR1 Capital Management LLC has acquired 1,341,394 shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) for approximately $6.14 million, establishing a 2.35% stake in the company. Institutional investors now hold 52.08% of Whitehawk Therapeutics. The company recently reported better-than-expected quarterly earnings and holds a consensus "Moderate Buy" rating from analysts with an average price target of $8.20.

    MarketBeat•8/26/26•
    Bullish

    WHWK | Whitehawk Therapeutics, Inc. Common Financials - Revenue Breakdown

    This article provides a detailed financial overview of Whitehawk Therapeutics, Inc. (WHWK), focusing on its revenue breakdown, institutional holdings, insider trading activity, and analyst ratings. It highlights the absence of specific revenue segment or geography data for WHWK. The company is described as an oncology therapeutics firm developing antibody-drug conjugate candidates for cancer treatment.

    Quiver Quantitative•8/23/26•
    Neutral

    Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

    Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has received a "Moderate Buy" consensus rating from eight brokerages, with six analysts recommending a buy, one a hold, and one a sell. The average 12-month price target is $8.20, significantly higher than its recent opening price of $4.76. The company recently exceeded quarterly earnings expectations, reporting an adjusted loss of $0.20 per share against an estimated $0.30 loss, and institutional investors hold a substantial 52.08% stake.

    MarketBeat•8/19/26•
    Bullish

    Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen

    Wall Street Zen has upgraded Whitehawk Therapeutics (NASDAQ:WHWK) from a "sell" to a "hold" rating. Despite this upgrade, the overall analyst consensus for WHWK remains a "Moderate Buy" with an average price target of $8.20. The company recently reported a quarterly loss of $0.20 per share, which was better than analysts' expectations.

    MarketBeat•8/9/26•
    Neutral

    Wall Street Analysts Are Bullish on Top Healthcare Picks

    Wall Street analysts are showing bullish sentiment towards several healthcare companies, specifically Whitehawk Therapeutics (WHWK), Corbus Pharmaceuticals (CRBP), and Doximity (DOCS). Analysts from JonesTrading and William Blair have reiterated Buy ratings, with strong average price targets suggesting significant upside potential for these stocks based on current market levels and expert ratings.

    The Globe and Mail•8/8/26•
    Bullish

    Frequently Asked Questions About WHWK

    Does WHWK pay dividends?
    Whitehawk Therapeutics, Inc. (WHWK) does not currently pay a regular dividend.
    What is WHWK's market cap?
    Whitehawk Therapeutics, Inc. (WHWK) has a market capitalization of $263.38M with a current stock price of $4.54.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In